• BFH772 (VEGFR2 inhibitor): Technical Use and Workflow Guide

  2026-07-29

  BFH772 is a highly selective VEGFR2 inhibitor designed for targeted suppression of VEGFR2-mediated angiogenesis, particularly in tumor model systems. It is most appropriate for workflows requiring high kinase selectivity and compatibility with DMSO or ethanol, but is not suitable for assays needing water solubility or broad-spectrum kinase inhibition.

• Neuromedin S (rat): Technical Guidance for GPCR Research

  2026-07-29

  Neuromedin S (rat) provides a chemically defined ligand for precise activation of neuromedin U receptor signaling in controlled GPCR/G protein studies, particularly in rat models. It is not intended for diagnostic, therapeutic, or cross-species applications and should only be applied in rigorously defined laboratory workflows.

• Cy5 Maleimide (Non-sulfonated): Precision Probe for Protein

  2026-07-28

  Cy5 maleimide (non-sulfonated) enables site-specific protein labeling through thiol-cysteine conjugation, offering robust fluorescence for imaging and quantitation. This reagent’s charge-selective partitioning properties are validated in condensate models, supporting reliable use in advanced molecular biology workflows.

• Antivirulence Myricetin Derivatives Counteract C. difficile

  2026-07-28

  This study identifies myricetin and its derivatives as novel antivirulence agents that directly inhibit the key C. difficile toxin TcdB, preserving gut microbiota and ameliorating infection in preclinical models. The findings support toxin-neutralizing strategies as viable alternatives to antibiotics for Clostridioides difficile infection.

• Efficient Synthesis of Deuterium-Labeled Degarelix Acetate

  2026-07-27

  This study establishes a practical, high-yield 13-step synthesis for deuterium-labeled degarelix acetate, a third-generation GnRH receptor antagonist. The innovation facilitates the use of isotopically labeled standards in advanced pharmacokinetic and metabolism research, supporting precise clinical studies in androgen-related diseases.

• RESTRICT-seq Reveals KAT6A Dependency in SCC Resistance

  2026-07-27

  The reference study introduces RESTRICT-seq, a time-gated CRISPR screening platform, to systematically uncover epigenetic dependencies in squamous cell carcinoma (SCC) resistance. Notably, KAT6A emerged as a central epigenetic vulnerability, highlighting the therapeutic potential of selective KAT6A inhibition and refining strategies for oncogene-induced senescence research.

• Protease Inhibitor Cocktail: Precision in Protein Degradatio

  2026-07-26

  APExBIO's Protease Inhibitor Cocktail (100X in DMSO, EDTA plus) redefines protein extraction workflows by providing robust, broad-spectrum protection against protease activity. This article explains how to maximize its application across Western blotting, co-immunoprecipitation, and cutting-edge cancer research, with actionable troubleshooting strategies for reproducibility.

• Berberine Modulates SASP Inflammation via RXRα/PPARγ/NEDD4 i

  2026-07-25

  The referenced study elucidates how berberine suppresses senescence-associated secretory phenotype (SASP)–driven inflammation in atherosclerosis by targeting the RXRα/PPARγ/NEDD4 signaling pathway. These mechanistic insights clarify the molecular underpinnings of berberine’s anti-inflammatory action and suggest new experimental strategies for dissecting SASP regulation in cardiovascular pathobiology.

• MK-571 (L-660,711): Unlocking Mechanistic Insights in Inflam

  2026-07-24

  This thought-leadership article explores the dual mechanistic power of MK-571 (L-660,711) as both a leukotriene D4 receptor antagonist and a multidrug resistance protein 1 (MRP1/ABCC1) inhibitor, bridging inflammation research and chemoresistance studies. Centered on translational strategies, the piece synthesizes recent discoveries on immune cell protection during chemotherapy, actionable experimental guidance, and future trajectories for safer, disease-modifying therapies. It uniquely contextualizes APExBIO’s offering within evolving research frontiers and delivers protocol-focused insight for the next generation of translational researchers.

• Leucovorin Calcium: Transforming Tumor Microenvironment Assa

  2026-07-24

  Explore how Leucovorin Calcium advances tumor microenvironment research by enabling nuanced modeling of folate metabolism and methotrexate resistance. This article offers a deep dive into innovative protocols and assembloid insights for scientific applications.

• IP6 Sensitizes HCC to Oxaliplatin via CCN2-LRP6-β-catenin In

  2026-07-23

  This study demonstrates that inositol hexaphosphate (IP6) enhances hepatocellular carcinoma (HCC) sensitivity to oxaliplatin by disrupting the CCN2-LRP6-β-catenin-ABCG1 signaling pathway. These findings provide mechanistic insight into overcoming intrinsic and acquired chemotherapy resistance in HCC, with implications for rational combination strategies.

• MK-5108 (VX-689): Selective Aurora A Inhibition in High-Risk

  2026-07-23

  Explore how MK-5108 (VX-689), a highly selective Aurora A kinase inhibitor, enables advanced modeling and targeting of high-risk, chemoresistant tumors. This article uniquely examines mechanistic insights, assay protocols, and translational implications beyond current guides.

• Milk-Derived Extracellular Vesicle Uptake in ISC Organoids

  2026-07-22

  This study introduces physiologically relevant porcine intestinal stem cell (ISC)-based organoid models to dissect how milk-derived extracellular vesicles (MEV) are internalized and influence stemness and differentiation. The work clarifies region- and polarity-specific uptake mechanisms, providing a rigorous foundation for future membrane trafficking and endocytosis research.

• Itraconazole in Candida Biofilm Assays: Advanced Protocols &

  2026-07-22

  Itraconazole stands out as a triazole antifungal agent for dissecting Candida biofilm resistance and overcoming experimental hurdles in antifungal drug interaction studies. This article delivers actionable protocols, translation of new autophagy findings, and troubleshooting expertise, empowering researchers with reproducible, high-impact workflows.

• Dual-Action Kinase Inhibitors Accelerate p38α MAPK Dephospho

  2026-07-21

  The referenced study reveals that certain kinase inhibitors, including those targeting p38α MAPK, can simultaneously block kinase activity and promote dephosphorylation by stabilizing specific inactive conformations. This dual-action mechanism suggests a new strategy for designing highly selective inhibitors with improved potency, which is relevant for inflammation, neurodegeneration, and type 1 diabetes research.

14831 records 1/989 page Next 12345 下5页 Last page